Kwon JJ, Hahn WC. A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective. Mol Cell Biol. 2021;41(4). doi:10.1128/MCB.00627-20
Cancer Program
Penter L, Zhang Y, Savell A, et al. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021. doi:10.1182/blood.2021010867
Bi K, He MX, Bakouny Z, et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. 2021. doi:10.1016/j.ccell.2021.02.015
Braun DA, Street K, Burke KP, et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021. doi:10.1016/j.ccell.2021.02.013
Dubrot J, Lane-Reticker SK, Kessler EA, et al. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. Immunity. 2021;54(3):571-585.e6. doi:10.1016/j.immuni.2021.01.001
Lazarian G, Yin S, Hacken ET, et al. A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell. 2021;39(3):380-393.e8. doi:10.1016/j.ccell.2021.02.003
Hahn WC, Bader JS, Braun TP, et al. An expanded universe of cancer targets. Cell. 2021;184(5):1142-1155. doi:10.1016/j.cell.2021.02.020
Jan M, Sperling AS, Ebert BL. Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide. Nat Rev Clin Oncol. 2021. doi:10.1038/s41571-021-00479-z
Graubert A, Aguet F, Ravi A, Ardlie KG, Getz G. RNA-SeQC 2: Efficient RNA-seq quality control and quantification for large cohorts. Bioinformatics. 2021. doi:10.1093/bioinformatics/btab135
He MX, Cuoco MS, Crowdis J, et al. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med. 2021;27(3):426-433. doi:10.1038/s41591-021-01244-6